Representing the SMART study investigator group. A phase III randomized mutlinational study of Monoclonal Antibody Immuno Therapy (SMART) with R1549 (90Y-huHMFG1) in patients with epithelial ovarian cancer (EOC)

M.V. Seiden, BB Benigno, LFAG Massuger, RHM Verheijen, A. Lopes, JT Soper, J. Markowska, R Vyzula, H. Lambert, AA Epenetos

Research output: Contribution to conferenceAbstractOther research output

Original languageEnglish
Publication statusPublished - 2004
EventASCO - New Orleans, United States
Duration: 4 Jun 20048 Jun 2004

Conference

ConferenceASCO
Country/TerritoryUnited States
CityNew Orleans
Period4/06/048/06/04

Cite this